Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
Epistemonikos ID: 01e6b4b2d5cf0aced6c6bb6c367bd6bd374d5a90
First added on: May 08, 2024